Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

On Friday, Immunic Inc (IMUX) stock saw a decline, ending the day at $1.19 which represents a decrease of $-0.02 or -1.65% from the prior close of $1.21. The stock opened at $1.21 and touched a low of ...

Leerink Partners has recently resumed Immunic Inc (IMUX) stock to Outperform rating, as announced on September 9, 2024, according to Finviz. Earlier, on August 27, 2024, B. Riley Securities had ...

Immunic to Participate in Industry, Scientific and Investor Conferences in November 29.10.2024 / 11:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to ...

Analyst Faisal Khurshid from Leerink Partners reiterated a Buy rating on Immunic (IMUX – Research Report) and keeping the price target at ...

July 24, 2024 — Scientists have discovered that the serrated edges of Komodo dragons' teeth are tipped with iron. The study gives new insight into how Komodo dragons keep their teeth razor-sharp ...

It’s a go for the two phase III Ensure studies of Immunic Inc.’s lead asset in treating relapsing multiple sclerosis. An ...

Immunic (IMUX) stock fell after the company said it plans to continue its Phase 3 ENSURE program for lead drug IMU-838 in ...

Shares of Immunic rose after the biopharmaceutical company reported a positive outcome in its interim analysis of a treatment for relapsing multiple sclerosis. The New York-based company's stock price ...

NEW YORK, Oct. 22, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline ...